Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vorinostat before surgery in treating patients with
triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery may
make the tumor smaller and reduce the amount of normal tissue that needs to be removed